Xponance Inc. Increases Stock Position in Elanco Animal Health Incorporated $ELAN

Xponance Inc. increased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 124.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,281 shares of the company’s stock after purchasing an additional 31,242 shares during the period. Xponance Inc.’s holdings in Elanco Animal Health were worth $1,133,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Elanco Animal Health in the first quarter valued at about $2,065,000. Goldman Sachs Group Inc. increased its position in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the period. Empowered Funds LLC raised its stake in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after acquiring an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Elanco Animal Health by 4.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares during the period. Finally, Teacher Retirement System of Texas grew its stake in shares of Elanco Animal Health by 4.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 75,382 shares of the company’s stock valued at $1,076,000 after purchasing an additional 3,110 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 1.6%

Elanco Animal Health stock opened at $24.47 on Thursday. The firm has a market capitalization of $12.17 billion, a price-to-earnings ratio of -50.98, a price-to-earnings-growth ratio of 3.17 and a beta of 1.83. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $27.72. The stock’s fifty day moving average is $24.40 and its two-hundred day moving average is $21.94.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the company earned $0.14 EPS. The firm’s revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Activity at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were acquired at an average cost of $21.30 per share, with a total value of $213,000.00. Following the transaction, the director owned 131,773 shares of the company’s stock, valued at $2,806,764.90. This represents a 8.21% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Robert M. Vanhimbergen bought 6,950 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the acquisition, the chief financial officer directly owned 124,233 shares of the company’s stock, valued at $2,688,402.12. The trade was a 5.93% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 43,450 shares of company stock valued at $937,883 in the last ninety days. 0.89% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ELAN. Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Wednesday, November 19th. Barclays assumed coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price on the stock. UBS Group increased their price target on shares of Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Morgan Stanley lifted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. increased their target price on Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.